European journal of nuclear medicine and molecular imaging · 2025
Potential utility of plasma pTau217 for assessing amyloid and tau biomarker profiles.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shin Daeun, Jang Hyemin, Yoo Heejin, Kim Kyungmin, Zetterberg Henrik, Blennow Kaj, Gonzalez-Ortiz Fernando, Ashton Nicholas J, Lee Eun Hye, Yun Jihwan, Na Duk L, Kim Hee Jin, Kang Sung Hoon, Kim Ko Woon, Kim Si Eun, Kim Yeo Jin, Kim Yeshin, Chun Min Young, Jung Na Yeon, Cho Soo Hyun, Kim Jun Pyo, Seo Sang Won, K-ROAD study groups
Аннотация
PURPOSE: Plasma phosphorylated tau 217 (pTau217) is a promising biomarker for Alzheimer's disease, reflecting both amyloid β (Aβ) and tau positron emission tomography (PET) results. While its diagnostic role is actively being investigated, this study aims to expand its application to staging disease progression and predicting cognitive decline.
METHODS: A total of 2,919 participants, primarily diagnosed as Alzheimer's clinical syndrome, were recruited. Plasma pTau217 was measured using the ALZpath assay, and its diagnostic accuracy for binary Aβ/tau (A/T) biomarker profiles and Aβ and tau PET staging was assessed using area under the curve (AUC). Longitudinal Mini-Mental State Examination (MMSE) changes according to plasma pTau217-based staging were analyzed.
RESULTS: Plasma pTau217 accurately predicted binary Aβ (AUC 0.96) and tau (AUC 0.90) PET positivity. Both the Aβ-positive/tau-positive (Aptau+/Tptau+) and Aβ-positive/tau-negative (Aptau+/Tptau-) groups, defined using plasma pTau217 cutoffs, showed significantly worse MMSE trajectories compared to the Aβ-negative/tau-negative (Aptau-/Tptau-) group (for Aptau+/Tptau+ vs. Aptau-/Tptau-, β = -1.061 ± 0.055; for Aptau+/Tptau- vs. Aptau-/Tptau-, β = -0.322 ± 0.070, all adjusted P < 0.001). However, its performance was less effective for Aβ and tau PET staging, particularly for medial temporal tau PET stage (AUC 0.71). Nevertheless, plasma pTau217-based staging distinguished longitudinal MMSE deterioration (all adjusted P < 0.001).
CONCLUSION: Plasma pTau217 is effective for predicting A/T biomarker profile and cognitive decline, though further study is needed to better explain its association with Aβ and tau PET staging.
CLINICAL TRIAL NUMBER: Not applicable.
METHODS: A total of 2,919 participants, primarily diagnosed as Alzheimer's clinical syndrome, were recruited. Plasma pTau217 was measured using the ALZpath assay, and its diagnostic accuracy for binary Aβ/tau (A/T) biomarker profiles and Aβ and tau PET staging was assessed using area under the curve (AUC). Longitudinal Mini-Mental State Examination (MMSE) changes according to plasma pTau217-based staging were analyzed.
RESULTS: Plasma pTau217 accurately predicted binary Aβ (AUC 0.96) and tau (AUC 0.90) PET positivity. Both the Aβ-positive/tau-positive (Aptau+/Tptau+) and Aβ-positive/tau-negative (Aptau+/Tptau-) groups, defined using plasma pTau217 cutoffs, showed significantly worse MMSE trajectories compared to the Aβ-negative/tau-negative (Aptau-/Tptau-) group (for Aptau+/Tptau+ vs. Aptau-/Tptau-, β = -1.061 ± 0.055; for Aptau+/Tptau- vs. Aptau-/Tptau-, β = -0.322 ± 0.070, all adjusted P < 0.001). However, its performance was less effective for Aβ and tau PET staging, particularly for medial temporal tau PET stage (AUC 0.71). Nevertheless, plasma pTau217-based staging distinguished longitudinal MMSE deterioration (all adjusted P < 0.001).
CONCLUSION: Plasma pTau217 is effective for predicting A/T biomarker profile and cognitive decline, though further study is needed to better explain its association with Aβ and tau PET staging.
CLINICAL TRIAL NUMBER: Not applicable.